$ Value
$0
Shares
100,000
Price
$0
Filed
May 22
Insider
Name
Venker Eric
Title
President & COO
CIK
0001801917
Roles
Transaction Details
Transaction Date
2025-05-20
Code
M
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
9,723,923
Footnotes
Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. | The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 25, 2024. | Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).
Filing Info
Venker Eric's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-04-20 | ROIV | M | $770K |
| 2026-04-20 | ROIV | ▼ | $5.9M |
| 2026-04-20 | ROIV | M | $0 |
| 2026-04-07 | IMVT | A | $0 |
| 2026-04-07 | IMVT | A | $0 |
| 2026-04-02 | IMVT | ▼ | $308K |
| 2026-04-02 | IMVT | ▼ | $35K |
| 2026-04-01 | IMVT | M | $5.3M |
| 2026-04-01 | IMVT | D | $8.4M |
| 2026-04-01 | IMVT | M | $0 |
Other Insiders at ROIV (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| MOMTAZEE JAMES C | — | — | 2026-04-17 |
| Fitzgerald Meghan | — | $1.9M | 2026-03-26 |
| Oren Ilan | — | — | 2026-04-17 |
|
Torti Frank
President and Vant Chair
|
— | — | 2026-03-31 |
|
Sukhatme Mayukh
President & CIO
|
— | — | 2026-03-31 |
|
Gline Matthew
CEO
|
— | $8.4M | 2026-04-16 |
|
Venker Eric
President & Immunovant CEO
|
— | $5.9M | 2026-04-20 |
| Epperly Melissa B, | — | — | 2026-04-17 |
|
Pulik Richard
CFO
|
— | — | 2026-04-20 |
|
Humes Jennifer
Chief Accounting Officer
|
— | $384K | 2026-04-20 |